Efficacy of Erqonasa ointment in osteoarthritis of the knee

Evaluation of efficacy of Erqonasa ointment in osteoarthritis of the knee joint: a randomized, double-blind, placebo-controlled trial: A Pilot Study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260425069160N1

Enrollment

Registered

2026-05-02

Start date

2026-05-02

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of knee. Unilateral primary osteoarthritis of knee

Interventions

Intervention 1: Intervention group: The intervention group will receive Erqonasa topical ointment manufactured by Kurdistan Shafa Pharmaceutical Company (Zemade Mafasel) three times a day for 4 weeks

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnose of primary osteoarthritis of knee Age above 40 years Pain exacerbation after discontinuation of NSAIDs or acetaminophen (at least two times) Written informed consent Pain severity based on VAS score between 4 and 10

Exclusion criteria

Exclusion criteria: Secondary Osteoarthritis Joint surgery or intra-articular injection in the past six months Joint replacement Severe systemic diseases (e.g., infection) Fibromyalgia or other disabling diseases Pregnancy and breastfeeding Uncontrolled cardiovascular disease Liver or kidney disease

Design outcomes

Primary

Measure	Time frame
Pain severity measured by VAS scale. Timepoint: Before intervention and four weeks after the start of intervention. Method of measurement: Pain severity measured using the VAS scale by physician assessment.	—

Secondary

Measure	Time frame
Joint stiffness by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Joint stiffness measured using the WOMAC questionnaire by physician assessment.;Physical function by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Physical function measured using the WOMAC questionnaire by physician assessment.;Pain severity by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Pain severity measured using the WOMAC questionnaire by physician assessment.;Comparison of oral acetaminophen consumption across three groups. Timepoint: The fourth weeks after the start of the study. Method of measurement: Oral acetaminophen consumption (mg/day) recorded based on patient self-report in data collection forms.	—

Measure

Time frame

Joint stiffness by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Joint stiffness measured using the WOMAC questionnaire by physician assessment.;Physical function by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Physical function measured using the WOMAC questionnaire by physician assessment.;Pain severity by WOMAC. Timepoint: Before intervention, two weeks and four weeks after the start of intervention. Method of measurement: Pain severity measured using the WOMAC questionnaire by physician assessment.;Comparison of oral acetaminophen consumption across three groups. Timepoint: The fourth weeks after the start of the study. Method of measurement: Oral acetaminophen consumption (mg/day) recorded based on patient self-report in data collection forms.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahyar Rezvani

Iran University of Medical Sciences

mahyar.rzv@gmail.com1475886671

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026